Dr. Christopher graduated from the University of Notre Dame with a bachelor’s degree in pre-professional studies and from the University of Virginia with a Doctor of Medicine (MD) degree. He completed postgraduate medical education in internal medicine at the Genesee Hospital, Rochester, NY, and infectious diseases at William Beaumont Hospital, Royal Oak, MI. He is certified by the American Board of Internal Medicine in internal medicine and infectious diseases.
His commitment to medical biological defense began during military service in the U. S. Air Force Medical Corps (1990-2011). He was a member of the Operational Medicine Division of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) (1996-2000), where he developed medical practice guidelines for treating biological casualties, and delivered medical training and education. He coordinated biodefense programs and was principal investigator for biodefense emergency use investigational new drug protocols at USAMRIID, Landstuhl Regional Medical Center, Germany (2000-2003) and Wilford Hall Medical Center, Lackland AFB, TX (2003-2006). He assisted the launch of Transformational Medical Technologies (TMT), an innovative DoD program to develop agile technology platforms and broad-spectrum medical countermeasures to enable rapid responses to biological warfare threats and emerging infectious diseases (2006-2010). He served as Special Assistant for Biological Defense in the Office of the Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction (Policy), where he supported the development and implementation of DoD and U.S. Government policies to enhance defenses against biological weapons and naturally occurring infectious diseases (2010-2011). He returned to TMT as a federal civilian in 2012 and continued serving through the transition of TMT into the MCS-JPMO. Dr. Christopher assumed his current role as Chief Medical Officer in June 2013.